Condition (MeSH)
Adenocarcinoma, Mucinous
ClinicalTrials.gov lists 56 trials for Adenocarcinoma, Mucinous or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
24 of the 56 trials are tagged with Adenocarcinoma, Mucinous itself; the rest are tagged with a narrower condition beneath it.
When did Adenocarcinoma, Mucinous trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 9 |
| 2025 | 3 |
| 2024 | 7 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 6 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 3 |
| 2016 | 1 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 21 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adenocarcinoma, Mucinous trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 8 |
| Phase 1/2 | 3 |
| Phase 2 | 16 |
| Phase 3 | 3 |
| Not applicable | 9 |
| Observational | 17 |
How many Adenocarcinoma, Mucinous trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 18 |
| Active, not recruiting | 5 |
| Completed | 13 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Adenocarcinoma, Mucinous trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| Apollo Therapeutics Ltd | 1 |
Which drugs are being tested for Adenocarcinoma, Mucinous? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| OXALIPLATIN | 2 |
| NIVOLUMAB | 2 |
| (nab)-paclitaxel | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Mitomycin C 0.02% | 3 |
| Gemcitabine/Gemzar | 2 |
| or carboplatin | 2 |
| N Acetylcysteine | 2 |
| Atezolizumab SC | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Adenocarcinoma, Mucinous trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile Neutropenia | 25 | 2 |
| Hypocalcemia | 22 | 1 |
| Lymphocyte Count Decreased | 18 | 1 |
| Aspartate Aminotransferase (AST) Increased | 17 | 1 |
| Anemia | 15 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Adenocarcinoma, Mucinous? (114)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | Yes |
| Feasibility, Indications, and Prognostic Significance of Selective Lateral Pelvic Lymph Node Dissection After Preoperative Chemoradiotherapy in Middle/Low Rectal Cancer: Results of a Multicenter Lateral Node Study in China. | Diseases of the colon and rectum | 2024 | Yes |
| Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms. | Nature communications | 2024 | Yes |
| Accurate prediction of histological grading of intraductal papillary mucinous neoplasia using deep learning. | Endoscopy | 2023 | Yes |
| Health-related quality of life and anxiety levels among patients under surveillance for intraductal papillary mucinous neoplasm. | BMC gastroenterology | 2023 | Yes |
Showing 5 of 114 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.